Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +35.91%
#2 Siren Siren +30.45%
#3 Purr Purr +28.61%
#4 OriginTrail OriginTrail +25.26%
#5 UnifAI Network UnifAI Network +16.95%
#6 ApeX ApeX +15.83%
#7 龙虾 (Lobster) 龙虾 (Lobster) +15.52%
#8 Morpho Morpho +14.85%
#9 Wrapped XPL Wrapped XPL +14.62%
#10 DigiByte DigiByte +14.48%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Hemab Therapeutics Holdings, Inc. Common Stock Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. Common Stock

COAG
Kedudukan dalam Saham #21709
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm... Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Harga Saham
$50.82
Disegerakkan terakhir: 2026-08-11
Modal Pasaran
$102.09M
Perubahan (1 hari)
1.90%
Perubahan (1 tahun)
-
Negara
US
Perdagangan Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

Kategori

Healthcare
Hasil untuk Hemab Therapeutics Holdings, Inc. Common Stock (COAG)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada Hemab Therapeutics Holdings, Inc. Common Stock, hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Hemab Therapeutics Holdings, Inc. Common Stock dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH